Core Viewpoint - Boston Scientific Corporation (NYSE:BSX) has experienced significant underperformance in the stock market, attributed to increased competition and macroeconomic uncertainties, particularly related to tariff investigations on medical devices [1][3]. Company Overview - Boston Scientific Corporation manufactures medical devices across various fields, including cardiology, neurology, and urology, with products such as heart-monitoring implants and spinal cord stimulators [3]. Market Position and Challenges - The company is facing challenges due to a Section 232 tariff investigation announced by the Trump administration, which has increased macro uncertainty in the medical device sector [3]. - Despite these challenges, Boston Scientific is well-positioned to manage tariffs due to its diverse supply chain and increased manufacturing footprint in the U.S. post-COVID [3]. Financial Outlook - Management has set long-term targets of 10% organic revenue growth, 50 basis points of annual margin expansion, and double-digit EPS growth through 2028, indicating a positive outlook for the company [3]. - The company has a strong pricing power and has largely mitigated the impact of tariffs thus far [3]. Growth Drivers - Boston Scientific's diversified growth profile across cardiology, electrophysiology, endoscopy, and urology franchises supports its favorable view in the market [3]. - The introduction of Farapulse, a pulsed-field ablation technology, is expected to drive significant growth in the electrophysiology segment in the coming years [3].

Core Viewpoint - Boston Scientific Corporation (BSX) is a global medical device company with a market cap of $138.8 billion, focusing on innovative technologies across various medical specialties, including cardiovascular and gastrointestinal conditions [1] Financial Performance - BSX shares have underperformed the broader market, decreasing 8.3% over the past 52 weeks, while the S&P 500 Index gained 15% [2] - Year-to-date, BSX shares have declined 1.6%, compared to the S&P 500's 1.9% return [2] - The company's stock also lagged behind the State Street Health Care Select Sector SPDR ETF's 5.3% rise over the past year [3] Recent Developments - On October 22, 2025, BSX shares rose nearly 4% after reporting Q3 2025 adjusted EPS of $0.75 and revenue of $5.07 billion, exceeding expectations [4] - The company raised its 2025 adjusted EPS forecast to a range of $3.02 - $3.04 and guided Q4 adjusted EPS of $0.77 - $0.79, above consensus estimates [4] - Strong demand for heart devices, particularly a 23.1% increase in electrophysiology sales driven by the Watchman and Farapulse systems, contributed to investor optimism [4] Analyst Ratings and Forecasts - Analysts expect BSX's adjusted EPS to grow 21.1% year-over-year to $3.04 for the fiscal year ending December 2025 [5] - The company has a promising earnings surprise history, beating consensus estimates in the last four quarters [5] - Among 31 analysts covering BSX, the consensus rating is a "Strong Buy," with 26 "Strong Buy" ratings, three "Moderate Buys," and two "Holds" [5] Price Targets - Bernstein analyst Lee Hambright maintained a "Buy" rating on BSX with a price target of $130 [6] - The mean price target of $125.53 indicates a 33.8% premium to BSX's current price levels [6] - The highest price target of $140 suggests a potential upside of 49.3% [6]

Core Insights - Hardman Johnston Global Advisors reported underperformance in its portfolio for Q3 2025, with a return of 5.02% net of fees, compared to 7.62% for the MSCI AC World Net Index [1] Company Overview - Boston Scientific Corporation (NYSE:BSX) is highlighted as a key stock in the investor letter, operating in the MedSurg and Cardiovascular segments of the medical device industry [2] - As of December 24, 2025, Boston Scientific's stock closed at $96.13 per share, with a market capitalization of $142.51 billion [2] Performance Analysis - Boston Scientific experienced a one-month return of -4.78% but gained 5.56% over the last 52 weeks [2] - The company was identified as a significant driver of underperformance within the healthcare sector, alongside Vertex Pharmaceuticals [3] Market Context - The Trump administration's Section 232 tariff investigation into medical devices has increased macroeconomic uncertainty, but Boston Scientific is well-positioned to manage potential tariffs due to its diverse supply chain and increased U.S. manufacturing footprint post-COVID [3] - The company has strong pricing power and has largely mitigated tariff impacts thus far [3] - The market is witnessing a rotation from medical devices to pharmaceuticals/biotech, influenced by recent deals such as the one between Pfizer and the Trump administration [3] Growth Prospects - Boston Scientific's diversified growth profile across various franchises, including cardiology, electrophysiology, endoscopy, and urology, supports a favorable outlook [3] - The introduction of Farapulse, a pulsed-field ablation technology, is expected to drive significant growth in the electrophysiology segment [3] - Management has set new long-term targets of 10% organic revenue growth, 50 basis points of annual margin expansion, and double-digit EPS growth through 2028, with a strong track record of exceeding previous targets [3]

Core Insights - Parnassus Investments reported that the S&P 500 Index increased by 8.12% in Q3 2025, driven by investor optimism regarding monetary easing, strong consumer demand, and solid corporate earnings [1] - The Parnassus Core Equity Fund (Investor Shares) returned 2.57% in Q3 2025, underperforming the S&P 500 Index, and has a year-to-date return of 9.89% compared to the index's 14.83% [1] Company Highlights - Boston Scientific Corporation (NYSE:BSX) experienced a one-month return of -4.86% but gained 5.89% over the last 52 weeks, with a market capitalization of $142.952 billion as of December 22, 2025 [2] - The company reported consolidated revenue of $5.065 billion for Q3 2025, reflecting a 20.3% growth compared to Q3 2024 [4] Investment Strategy - The Parnassus Core Equity Fund made strategic moves in the Health Care sector by trimming positions in Eli Lilly and Stryker to initiate a position in Boston Scientific Corporation, citing its first-mover advantage and robust clinical data as key growth drivers [3] - Management's focus on disciplined R&D and M&A has led to organic sales growth and margin expansion, positioning Boston Scientific for durable growth [3]

Core Viewpoint - Boston Scientific Corporation (NYSE:BSX) is highlighted as a top investment opportunity in the healthcare AI sector, with TD Cowen reaffirming a Buy rating and setting a price target of $115, naming it their "Best Idea for 2026" [1] Group 1: Growth Potential - TD Cowen describes Boston Scientific as "the most attractive growth story in the medical devices sector," supported by expectations of over 10% organic sales growth annually, 50 basis points of yearly operating margin expansion, and double-digit EPS growth [1][2] - Analysts anticipate that Boston Scientific will maintain double-digit organic revenue growth through 2026, despite facing tougher year-over-year comparisons [1] Group 2: Competitive Advantage - Boston Scientific's proven history of strong double-digit earnings growth justifies higher valuation multiples due to its "scarcity value," as few companies can match this reliable high growth [2] - Key products driving this growth include Farapulse for atrial fibrillation treatment and Watchman for stroke prevention [2] Group 3: Innovation and Market Strategy - At the 7th Annual Wolfe Research Healthcare Conference, Boston Scientific's management discussed the company's innovation pipeline and market expansion strategies, particularly in electrophysiology [3] - The Farapulse pulsed field ablation (PFA) system is projected to exceed 50% market penetration in the US by the end of 2025 [3] - Historical trials for the Watchman device were discussed, highlighting limitations from older device generations and post-procedure regimens [3] Group 4: Technological Integration - Boston Scientific develops medical devices across various fields, including cardiology, endoscopy, neuromodulation, and urology, utilizing machine learning, natural language processing, and computer vision to enhance medical imaging and patient management [4]

Financial Data and Key Metrics Changes - The company reported strong growth in the electrophysiology (EP) business, with growth rates approximately double the market average, driven by the FARAPULSE ecosystem [2][5] - The approval of persistent atrial fibrillation (AF) in the U.S. is expected to further enhance market penetration [5] Business Line Data and Key Metrics Changes - The FARAPULSE product line has seen significant adoption, particularly in the U.S. where penetration quickly surpassed 50% [4] - The Watchman franchise is projected to grow at over 20% annually, contingent on positive outcomes from the OPTION and CHAMPION trials [13][17] Market Data and Key Metrics Changes - The global electrophysiology market is valued at $13 billion, with $9 billion attributed to AF and $4 billion to other indications [9] - The renal denervation market is being revisited due to evolving clinical data and the high prevalence of hypertension, with one in four adult Americans affected [37] Company Strategy and Development Direction - The company aims to maintain category leadership across various medical device segments, including interventional cardiology and electrophysiology [67] - There is a focus on expanding the FARAPULSE ecosystem and entering adjacent markets, with a strong emphasis on innovation and product development [1][9] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a highly competitive landscape in cardiology but expresses confidence in their understanding of upcoming competition and their strategic positioning [10][12] - The company is preparing for a shift of inpatient procedures to outpatient settings, aligning their product ecosystem accordingly [48][49] Other Important Information - The company is actively investing in artificial intelligence to enhance product development and operational efficiency [61][64] - The upcoming CHAMPION trial is expected to significantly impact the Watchman market, potentially expanding the eligible patient population to approximately 20 million globally [17] Q&A Session Summary Question: What is the long-term growth outlook for the Watchman franchise? - The Watchman franchise is expected to grow over 20% annually, depending on the outcomes of the OPTION and CHAMPION trials [13][17] Question: How does the company view the competitive landscape in electrophysiology? - The company recognizes the competitive nature of the market but believes their unique product offerings and ecosystem will maintain their leadership position [10][12] Question: What is the timeline for the Seismic device in interventional cardiology? - The Seismic device is currently enrolling in the Fracture ID study, with a commercial launch anticipated in the first half of 2027 [30]

Core Insights - The inclusion of atrial fibrillation (AF) catheter ablation in the ASC Covered Procedures List (CPL) marks a significant shift towards outpatient treatment for cardiac electrophysiology, effective January 1, 2026 [2][33] - This regulatory change is seen as a watershed event, driven by multiple trends converging between 2023 and 2025, facilitating the outpatient transition for electrophysiology [11][33] Group 1: Impact on Companies - The three leading companies in the PFA space—Boston Scientific, Medtronic, and Johnson & Johnson MedTech—are expected to be the primary beneficiaries of this reimbursement update [5][21] - Boston Scientific is focusing on its Farapulse brand as a key growth engine, with the ASC payment change enhancing its operational pathways [6] - Medtronic views the ASC setting as an additional market expansion opportunity, with its Affera and PulseSelect systems driving revenue growth [7] - Johnson & Johnson MedTech supports the decision, emphasizing its goal to shape the future of cardiac ablation in the ASC environment [8] Group 2: Trends in Outpatient Electrophysiology - The ASC model is expanding in the U.S., recognized for its efficiency, predictability, and cost control, making it a suitable environment for cardiac ablation procedures [2] - The transition to PFA technology has reduced operation times and complication risks, aligning with the ASC's safety and high turnover logic [14][18] - The payment system is evolving towards outpatient pathways, with CMS opening reimbursement for complex procedures since 2021 [15][21] Group 3: Market Dynamics and Future Outlook - The inclusion of AF ablation in the CPL is expected to increase patient access to treatment, breaking through previous capacity constraints in the healthcare system [22] - Competition is shifting from technology leadership to scene leadership, with companies focusing on comprehensive solutions rather than just energy source differences [23] - The ASC environment may reshape physician skill requirements, favoring standardized processes over complex decision-making [24] - Companies are likely to accelerate the development of differentiated product lines tailored for ASC settings, leading to a more outpatient-oriented business model [25][30]

Core Insights - Boston Scientific Corporation (NYSE:BSX) is identified as a strong investment opportunity with a Buy rating and a price target of $132 as of October 23, 2023 [1][2] Financial Performance - The company reported fiscal third quarter 2025 results on October 22, exceeding EPS and revenue estimates by $0.04 and $90.87 million, respectively [2] - The EPS of $0.75 surpassed the firm's estimate of $0.70, attributed to significant improvements in gross margins [2] Growth Projections - Boston Scientific raised its full-year guidance, projecting a 20% growth and an adjusted EPS in the range of $3.02 to $3.04 [3] - Key growth drivers include the Watchman and Farapulse products, ongoing investments in growth, and anticipated label expansions of existing products [3] Company Overview - Boston Scientific develops and markets medical devices across various interventional specialties, addressing conditions in gastrointestinal, urological, neurological, and cardiovascular areas through minimally invasive technologies [4]

Core Viewpoint - Boston Scientific has raised its fiscal year 2025 profit outlook to between $3.02 and $3.04 per share, driven by strong performance in its cardiovascular business [1] Financial Performance - Boston Scientific reported total sales exceeding $5 billion in Q3 2025, marking a 20.4% increase from $4.2 billion in Q3 2024 [3] - Revenue from the cardiovascular portfolio surpassed $3.3 billion, reflecting a 22.4% rise from $2.7 billion in Q3 2024 [3] - The MedSurg portfolio revenue grew to approximately $1.7 billion, a 16.4% increase year-over-year, while the urology segment rose by 28.1% to $682 million [6] Market Response - Following the Q3 results announcement, Boston Scientific's share price increased by over 4% to around $104 per share, with a market capitalization of approximately $153 billion [2] Product Performance - The Farapulse pulsed-field ablation (PFA) system has treated 500,000 patients, demonstrating consistent real-world results [3] - Adoption of the OPAL HDx Mapping System is contributing to the growth of Farapulse, with one in three Farapulse accounts utilizing the integrated FARAWAVE NAV PFA catheter and OPAL device [4] Competitive Landscape - Medtronic has also raised its FY26 profit outlook, reflecting growth in its cardiovascular portfolio, which is competing with Boston Scientific's Farapulse [4][5]

Core Insights - Boston Scientific Corporation (BSX) has a market capitalization of $144.2 billion and specializes in innovative medical devices across various interventional medical specialties [1] - The company is expected to announce its fiscal Q3 2025 earnings on October 22, with analysts predicting an adjusted EPS of $0.71, reflecting a 12.7% increase from the previous year [2] - For fiscal 2025, the anticipated adjusted EPS is projected to be $2.98, an 18.7% increase from $2.51 in fiscal 2024 [3] Stock Performance - Over the past 52 weeks, BSX shares have increased by 14.5%, underperforming the S&P 500 Index's 17.1% rise but outperforming the Health Care Select Sector SPDR Fund's 4.6% decline [4] - Following the Q2 2025 earnings report, BSX shares surged by 4.5% after announcing an adjusted EPS of $0.75 and revenue of $5.1 billion, along with a raised profit outlook for 2025 [5] Analyst Ratings - The consensus rating for BSX stock is "Strong Buy," with 27 out of 32 analysts recommending this rating, while the average price target is $126.16, indicating a potential upside of 30.5% from current levels [6]